Jon Cuthbert

Analysts warn Russia’s digital ruble may curb growth of the MIR card network and reshape the country’s cashless payments sector.

CurveBeam AI (ASX:CVB) has received formal approval under China's outbound direct investment framework for a strategic equity investment from Shandong WeiYing Intelligent Medical Technology.

Summit Minerals (ASX:SUM) announced plans to seek shareholder approval at its upcoming general meeting to change its name to Western Ridge Resources.

Australian antiviral developer Island Pharmaceuticals (ASX:ILA) has been granted US Patent Number 12,508,266 by the US Patent and Trademark Office for the use of Galidesivir.

Neuren Pharmaceuticals (ASX:NEU) announced that results from its Phase 2 clinical trial of NNZ-2591 in children and adolescents with Phelan-McDermid syndrome have been published in Neurology Genetics

A French court hears charges against a hypnotherapist accused of drugging and sexually abusing multiple women.

UC San Diego Health has commenced clinical use of 4DMedical’s (ASX:4DX) advanced respiratory imaging technology, CT:VQ.

Solstice Minerals (ASX:SLS) has recommenced Phase 1 reverse circulation drilling at its 100%-owned Nanadie Copper-Gold Project.

Johnson & Johnson (NYSE:JNJ) announced on Tuesday, January 6, 2026, that its Phase 2b JASMINE study of nipocalimab in adults with moderate-to-severe systemic lupus erythematosus (SLE) met its primary and key secondary endpoints.

Abpro Holdings (NASDAQ:ABP) and South Korean biopharma giant Celltrion announced on January 6, 2026, that the U.S. FDA has cleared the Investigational New Drug (IND) application for ABP-102 (CT-P72).

This clearance transitions Abpro’s lead oncology program into the clinic, targeting a wide array of HER2-positive solid tumors, including breast, gastric, colorectal, and pancreatic cancers.